Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Future Developments in Neoadjuvant Therapy for Triple-Negative Breast Cancer.

Moore-Smith L, Forero-Torres A, Stringer-Reasor E.

Surg Clin North Am. 2018 Aug;98(4):773-785. doi: 10.1016/j.suc.2018.04.004. Review.

PMID:
30005773
2.

Silencing of TGF-β1 in tumor cells impacts MMP-9 in tumor microenvironment.

Moore-Smith LD, Isayeva T, Lee JH, Frost A, Ponnazhagan S.

Sci Rep. 2017 Aug 17;7(1):8678. doi: 10.1038/s41598-017-09062-y.

3.

Micro-RNA Profiling as a Predictor of Clinical Outcomes for Head and Neck Cancer Patients.

Isayeva T, Brandwein-Gensler M, Somarathna M, Moore-Smith LD, Lee T.

Curr Pharm Des. 2017;23(32):4729-4744. doi: 10.2174/1381612823666170601100633.

PMID:
28571552
4.

SMAD4 is a potential prognostic marker in human breast carcinomas.

Liu NN, Xi Y, Callaghan MU, Fribley A, Moore-Smith L, Zimmerman JW, Pasche B, Zeng Q, Li YL.

Tumour Biol. 2014 Jan;35(1):641-50. doi: 10.1007/s13277-013-1088-1. Epub 2013 Aug 24.

5.

TGFBR1 signaling and breast cancer.

Moore-Smith L, Pasche B.

J Mammary Gland Biol Neoplasia. 2011 Jun;16(2):89-95. doi: 10.1007/s10911-011-9216-2. Epub 2011 Apr 5. Review.

Supplemental Content

Loading ...
Support Center